[ad_1]
This phase 3 trial, that is, the massive trial stage, “has not met its primary or secondary endpoint, compared to placebo,” the French group said in a statement.
At the moment, Sanofi and the US laboratory Regeneron, which co-developed this drug launched in 2017 to treat rheumatoid arthritis, “do not intend to carry out other clinical studies on Kevzara in the treatment of COVID-19”, it is mentioned in the note.
This study, which evaluates the efficacy of Kevzara in the treatment of severe forms of COVID-19, included 420 patients and was carried out in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia and Spain.
Although “it did not give us the results we expected, we are proud of the work carried out by the team that was in charge of deepening our knowledge about the potential use of Kevzara in the treatment of covid-19,” said John Reed, head of research and development at Sanofi. , quoted in the press release.
The covid-19 pandemic has already claimed at least 847,071 deaths and infected more than 25.2 million people in 196 countries and territories, according to a report by the French news agency AFP.
The disease is transmitted by a new coronavirus detected in late December in Wuhan, a city in central China.
